Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems-Trading Strong Earnings Growth and Momentum -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (1890)	1/16/2001 5:34:36 PM
From: Jenna	Read Replies (1) \| Respond to of 6445

THOR nice one also. Looking for increased revenue. Already trading above its 20 day moving average all indicators are bullish and THOR is under accumulation. Thoratec Laboratories Expects 40% Revenue Growth in 2001, to $42 to $44 Million, and 100% Growth in Earnings; Provides Update on Thermo Cardiosystems Transaction PLEASANTON, Calif., Jan. 16 /PRNewswire/ -- Thoratec Laboratories Corporation (Nasdaq: THOR - news), said today that based on growing demand for the Thoratec® Ventricular Assist Device (VAD) System and recent approval to begin marketing its Vectra(TM) vascular access graft in the U.S., the company expects its stand alone fiscal 2001 revenues will be between $42 million and $44 million, a roughly 40 percent growth rate over the prior year, and that earnings per share will be $0.21-$0.24, or double the prior year, without regard to taxes and certain one-time charges. ``The market for mechanical assist devices, and the Thoratec VAD System in particular, continues to be very strong -- both here and abroad -- and our device is now being used by more than 165 centers in the U.S. and Europe. In addition, we have received very positive initial market response to our Vectra graft, which recently received U.S. approval. We are also hopeful that our TLC-II® portable VAD driver will receive FDA approval in the very near future,'' said D. Keith Grossman, president and chief executive officer. Last week, Thoratec announced that revenues for the fourth quarter of fiscal 2000 were a record $9.4 million and a record $30.4 million for all of fiscal 2000, growth of 31 percent and 35 percent, respectively, and that the company expects to report fourth quarter earnings per share of $0.05-$0.06, before taxes and one-time costs related to its proposed merger with Thermo Cardiosystems Inc. (AMEX: TCA - news). The company is now updating this information to an earnings estimate of $0.06 to $0.07 per share, before the same taxes and one-time expenses. The company will report complete financial results for the fourth quarter and all of fiscal 2000 on January 22.

To: Jenna who wrote (1890)	1/16/2001 5:54:27 PM
From: Jenna	Respond to of 6445

Pivotal Corporation: Invitation To Second Quarter Fiscal 2001 Earnings Call VANCOUVER, B.C.--(BUSINESS WIRE)--Jan. 3, 2001--PivotalCorp (NASDAQ:PVTL - news; TSE:PVT. - news) Members of the Investment Community, Pivotal Corporation (NASDAQ NM:PVTL - news; TSE:PVT. - news) plans to announce the second quarter fiscal 2001 earnings results after the closing of the market on Monday, January 22, 2001.